Proteotech Inc.

Cognitive Clarity Inc.

Other

Protamed, Inc.

Thomas P Lake

Alan D Snow

Gerardo M Castillo

Beth P Nguyen

Virginia J Sanders

Joel Cummings

Qubai Hu

Lesley Larsen

Judy Cam

Luke A Esposito

F Michael Hudson

David Samuel Larsen

Stephen D Lorimer

Rex T Weavers

Manfred Weigele

David Llewellyn Coffen

Charlotte Coffen, Legal Representative

Marisa C Yadon

Anil M Kumar

Franz F Hefti

Seok-Rye Choi

Ximin Li

Kelsey Hanson

Esposito A Luke

Geoffrey Golding

Anil Kumar

David S Larsen

D Snow Alan

Composition and methods for treating brain 'plaques' and 'tangles' in a patient or an animal wherein the method comprises administration of a therapeutically effective amount of a composition comprising Uncariaextract and an oolong tea extract.

Compositions and methods for the treatment of plaques and tangles in humans and animals

Methods of treating the formation, deposition, accumulation, or persistence of beta-amyloid containing plaques and tau protein containing tangles including the step of treating the plaques or tangles with an effective amount of a composition comprising anextract and an oolong tea extract. Compositions containing anextract in combination with an oolong tea extract.

Composition and methods for treating brain 'plaques' and 'tangles' in a patient or an animal wherein the method comprises administration of a therapeutically effective amount of a composition comprisingextract and an oolong tea extract.

Compositions and methods for the treatment of 'plaques and tangles' in humans and animals

This invention relates to the use of bis- and tris-dihydroxyaryl compounds as well as sulfonamides, heteroaryls, tricycloalkyl and their analogs and pharmaceutically acceptable salts, for modulating tau aggregation and alleviating tauopathies, such as Alzheimer's disease (AD), Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and familial frontotemporal dementia/Parkinsonism linked to chromosome 17 (FTDP-17), amyotrophic lateral sclerosis/Parkinsonism-dementia complex, argyrophilic grain dementia, dementia pugilistic, diffuse neurofibrillary tangles with calcification, progressive subcortical gliosis and tangle only dementia.

Compounds and compositions for use a modulators of tau aggregation and alleviation of tauopathies

Compounds and their pharmaceutically acceptable salts for treatment of tauopathies, such as Alzheimer's disease, Pick's disease, progressive supranuclear palsy, corticobasal degeneration, familial frontotemporal dementia/Parkinsonism linked to chromosome 17, amyotrophic lateral sclerosis/Parkinsonism-dementia complex, argyrophilic grain dementia, dementia pugilistic, diffuse neurofibrillary tangles with calcification, progressive subcortical gliosis and tangle only dementia.

Compounds for the treatment of neurodegenerative diseases

Compounds and their pharmaceutically acceptable salts for treatment of &#x3b2;-amyloid diseases, such as observed in Alzheimer's disease and synucleinopathies, such as Parkinson's disease.

Caffeinated compounds and compositions for treatment of amyloid diseases and synucleinopathies

Compounds and their pharmaceutically acceptable salts for treatment of synucleinopathies, such as Parkinson's disease and tauopathies.

The use of 3,4,3',4&#x2032;-tetrahydroxychalcone in the treatment of amyloid diseases, especially A&#x3b2; amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease.

Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's

Dihydroxyaryl compounds and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

Compounds, compositions, and methods for the treatment of &#x3b2;-amyloid diseases and synucleinopathies

Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially A&#x3b2; amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes, and Parkinson's disease

Dihydroxyaryl compounds and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of &#x3b2;-amyloid diseases, such as observed in Alzheimer's disease, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies

Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes and Parkinson's disease

Dihydroxyaryl compounds and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of IAPP or amylin fibril diseases, and the manufacture of medicaments for such treatment.

Growing community of inventors

Bothell, WA, United States of America

Thomas P Lake